{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:20:43Z","timestamp":1768566043086,"version":"3.49.0"},"posted":{"date-parts":[[2023,12,18]]},"group-title":"Pathology","reference-count":40,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec id=\"s1\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\n                    Emerging artemisinin resistance and diagnostic resistance are a threat to malaria control in Africa.\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    kelch13 (K13) propeller-domain mutations that confer artemisinin partial resistance have emerged in Africa. K13-561H was initially described at a frequency of 7.4% from Masaka in 2014-2015 but not present in nearby Rukara. By 2018, 19.6% of isolates in Masaka and 22% of isolates in Rukara contained the mutation. Longitudinal monitoring is essential to inform control efforts. In Rukara, we sought to assess recent K13-561H prevalence changes, as well as for other key mutations. Prevalence of\n                    <jats:italic>hrp2\/3<\/jats:italic>\n                    deletions was also assessed.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec id=\"s2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    We genotyped samples collected in Rukara in 2021 for key artemisinin and partner drug resistance mutations using molecular inversion probe assays and for\n                    <jats:italic>hrp2\/3<\/jats:italic>\n                    deletions using qPCR.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec id=\"s3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    Clinically validated K13 artemisinin partial resistance mutations continue to increase in prevalence with the overall level of artemisinin resistance mutant infections reaching 32% in Rwanda. The increase appears to be due to the rapid emergence of K13-675V (6.4%, 6\/94 infections), previously not observed, rather than continued expansion of 561H (23.5% 20\/85). Mutations to partner drugs and other antimalarials were variable, with high levels of multidrug resistance 1 (MDR1) N86 (95.5%) associated with lumefantrine resistance and dihydrofolate reductase (DHFR) 164L (24.7%) associated with antifolate resistance, but low levels of amodiaquine resistance polymorphisms with chloroquine resistance transporter (CRT\n                    <jats:italic>)<\/jats:italic>\n                    76T: at 6.1% prevalence. No\n                    <jats:italic>hrp2<\/jats:italic>\n                    or\n                    <jats:italic>hrp3<\/jats:italic>\n                    gene deletions associated with diagnostic resistance were found.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec id=\"s4\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>\n                    Increasing prevalence of artemisinin partial resistance due to K13-561H and the rapid expansion of K13-675V is concerning for the longevity of artemisinin effectiveness in the region. False negative mRDT results do not appear to be an issue with no\n                    <jats:italic>hrp2 or hpr3<\/jats:italic>\n                    deletions detected. Continued molecular surveillance in this region and surrounding areas is needed to follow artemisinin resistance and provide early detection of partner drug resistance, which would likely compromise control and increase malaria morbidity and mortality in East Africa.\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.12.17.23300081","type":"posted-content","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T04:20:11Z","timestamp":1702959611000},"source":"Crossref","is-referenced-by-count":3,"title":["Expansion of Artemisinin Partial Resistance Mutations and Lack of Histidine Rich Protein-2 and -3 Deletions in\n                  <i>Plasmodium falciparum infections<\/i>\n                  from Rukara, Rwanda"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5223-6780","authenticated-orcid":false,"given":"Cecile","family":"Schreidah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2498-4705","authenticated-orcid":false,"given":"David","family":"Giesbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Gashema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeva","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharcisse","family":"Munyaneza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude Mambo","family":"Muvunyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyaw","family":"Thwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Mazarati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-8204","authenticated-orcid":false,"given":"Jeffrey","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0591-0850","authenticated-orcid":false,"given":"Jonathan J","family":"Juliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine","family":"Karema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023122107451021000_2023.12.17.23300081v1.1","unstructured":"World malaria report 2022 [Internet]. [cited 2023 Oct 24]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240064898"},{"key":"2023122107451021000_2023.12.17.23300081v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104275"},{"key":"2023122107451021000_2023.12.17.23300081v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2239"},{"key":"2023122107451021000_2023.12.17.23300081v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211803)"},{"issue":"10","key":"2023122107451021000_2023.12.17.23300081v1.5","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","article-title":"Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia","volume":"8","year":"2023","journal-title":"Nat Microbiol"},{"key":"2023122107451021000_2023.12.17.23300081v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1005-2"},{"key":"2023122107451021000_2023.12.17.23300081v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature12876"},{"key":"2023122107451021000_2023.12.17.23300081v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70049-6"},{"key":"2023122107451021000_2023.12.17.23300081v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00142-0"},{"key":"2023122107451021000_2023.12.17.23300081v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314981"},{"key":"2023122107451021000_2023.12.17.23300081v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa687"},{"key":"2023122107451021000_2023.12.17.23300081v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101746"},{"key":"2023122107451021000_2023.12.17.23300081v1.13","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-0483"},{"issue":"1","key":"2023122107451021000_2023.12.17.23300081v1.14","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1038\/s41467-022-33873-x","article-title":"Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda","volume":"13","year":"2022","journal-title":"Nat Commun"},{"key":"2023122107451021000_2023.12.17.23300081v1.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210956"},{"key":"2023122107451021000_2023.12.17.23300081v1.16","doi-asserted-by":"crossref","unstructured":"Juliano JJ , Giesbrecht DJ , Simkin A , Fola AA , Lyimo BM , Perus D , et al. Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of sulphadoxine-pyrimethamine resistance mutations in northwest Tanzania [Internet]. Infectious Diseases (except HIV\/AIDS); 2023 Nov [cited 2023 Nov 9]. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.11.07.23298207","DOI":"10.1101\/2023.11.07.23298207"},{"issue":"4","key":"2023122107451021000_2023.12.17.23300081v1.17","doi-asserted-by":"crossref","first-page":"ofad149","DOI":"10.1093\/ofid\/ofad149","article-title":"Examining the Early Distribution of the Artemisinin-Resistant Plasmodium falciparum kelch13 R561H Mutation in Areas of Higher Transmission in Rwanda","volume":"10","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2023122107451021000_2023.12.17.23300081v1.18","doi-asserted-by":"publisher","DOI":"10.3201\/eid2701.203527"},{"issue":"1","key":"2023122107451021000_2023.12.17.23300081v1.19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12936-021-03812-0","article-title":"Impact of Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions on malaria control worldwide: a systematic review and meta-analysis","volume":"20","year":"2021","journal-title":"Malar J"},{"key":"2023122107451021000_2023.12.17.23300081v1.20","doi-asserted-by":"crossref","unstructured":"Watson OJ , Tran TNA , Zupko RJ , Symons T , Thomson R , Visser T , et al. Global risk of selection and spread of Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions [Internet]. Infectious Diseases (except HIV\/AIDS); 2023 Oct [cited 2023 Nov 13]. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.10.21.23297352","DOI":"10.1101\/2023.10.21.23297352"},{"key":"2023122107451021000_2023.12.17.23300081v1.21","unstructured":"Organization WH . Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019) [Internet]. World Health Organization; 2020 [cited 2023 Oct 24]. Available from: https:\/\/iris.who.int\/handle\/10665\/336692"},{"issue":"3","key":"2023122107451021000_2023.12.17.23300081v1.22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2144\/000114018","article-title":"Chelex 100 as a Medium for Simple Extraction of DNA for PCR-Based Typing from Forensic Material","volume":"54","year":"2013","journal-title":"BioTechniques"},{"issue":"6","key":"2023122107451021000_2023.12.17.23300081v1.23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/infdis\/jiy223","article-title":"Drug-Resistance and Population Structure of Plasmodium falciparum Across the Democratic Republic of Congo Using High-Throughput Molecular Inversion Probes","volume":"218","year":"2018","journal-title":"J Infect Dis"},{"key":"2023122107451021000_2023.12.17.23300081v1.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2418-2423.2003"},{"key":"2023122107451021000_2023.12.17.23300081v1.25","doi-asserted-by":"crossref","unstructured":"Grignard L , Nolder D , Sep\u00falveda N , Berhane A , Mihreteab S , Kaaya R , et al. A novel multiplex qPCR assay for detection of Plasmodium falciparum with histidine-rich protein 2 and 3 (pfhrp2 and pfhrp3) deletions in polyclonal infections. EBioMedicine. 2020 May;55:102757.","DOI":"10.1016\/j.ebiom.2020.102757"},{"issue":"9","key":"2023122107451021000_2023.12.17.23300081v1.26","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/infdis\/jiz335","article-title":"pfhrp2 and pfhrp3 Gene Deletions That Affect Malaria Rapid Diagnostic Tests for Plasmodium falciparum: Analysis of Archived Blood Samples From 3 African Countries","volume":"220","year":"2019","journal-title":"J Infect Dis"},{"key":"2023122107451021000_2023.12.17.23300081v1.27","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0850-9"},{"key":"2023122107451021000_2023.12.17.23300081v1.28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151565"},{"key":"2023122107451021000_2023.12.17.23300081v1.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101717"},{"key":"2023122107451021000_2023.12.17.23300081v1.30","doi-asserted-by":"crossref","unstructured":"Zupko RJ , Nguyen TD , Ngabonziza JCS , Kabera M , Li H , Tran TNA , et al. Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda. Nat Med [Internet]. 2023 Sep 21 [cited 2023 Nov 13]; Available from: https:\/\/www.nature.com\/articles\/s41591-023-02551-w","DOI":"10.1101\/2022.12.12.22283369"},{"key":"2023122107451021000_2023.12.17.23300081v1.31","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis747"},{"key":"2023122107451021000_2023.12.17.23300081v1.32","doi-asserted-by":"publisher","DOI":"10.1086\/498249"},{"key":"2023122107451021000_2023.12.17.23300081v1.33","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4523-0"},{"issue":"12","key":"2023122107451021000_2023.12.17.23300081v1.34","first-page":"e01047","article-title":"Associations between Malaria-Preventive Regimens and Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Ugandan Pregnant Women","volume":"64","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122107451021000_2023.12.17.23300081v1.35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00498-09"},{"issue":"1","key":"2023122107451021000_2023.12.17.23300081v1.36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12936-017-1812-1","article-title":"Travel and the emergence of high-level drug resistance in Plasmodium falciparum in southwest Uganda: results from a population-based study","volume":"16","year":"2017","journal-title":"Malar J"},{"key":"2023122107451021000_2023.12.17.23300081v1.37","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182011000746"},{"issue":"1","key":"2023122107451021000_2023.12.17.23300081v1.38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12936-023-04487-5","article-title":"A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria","volume":"22","year":"2023","journal-title":"Malar J"},{"key":"2023122107451021000_2023.12.17.23300081v1.39","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky258"},{"key":"2023122107451021000_2023.12.17.23300081v1.40","doi-asserted-by":"crossref","first-page":"102076","DOI":"10.1016\/j.tmaid.2021.102076","article-title":"A comparative study of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) blood levels and peripheral blood parasitemia as parameters of disease severity in individuals with imported falciparum malaria","volume":"42","year":"2021","journal-title":"Travel Med Infect Dis"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.12.17.23300081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:46:52Z","timestamp":1768506412000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.12.17.23300081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1101\/2023.12.17.23300081","relation":{},"subject":[],"published":{"date-parts":[[2023,12,18]]},"subtype":"preprint"}}